严重慢性肾脏病患者接种13价肺炎球菌结合疫苗后对肺炎链球菌的调理吞噬活性:原住民与非原住民比较
本研究为既往临床试验的随访分析,评估57例既往接种PPV23(组1)和72例未接种PPV23(组2)的严重慢性肾脏病患者接种PCV13后第28天和第365天的调理吞噬活性(OPA)滴度。结果显示PCV13可诱导两组产生功能性抗体,但既往PPV23对多个血清型的OPA应答产生负面影响,持续至少一年。原住民患者基线及接种后部分血清型GMT显著高于非原住民。
要点
- 严重慢性肾脏病患者接种PCV13后可产生功能性肺炎球菌抗体。
- 既往接种PPV23对PCV13多个血清型OPA应答有负面影响,持续至少1年。
- 原住民患者部分血清型GMT在基线及接种后28天显著高于非原住民。
核心结论
- 严重慢性肾脏病患者接种PCV13后可产生功能性肺炎球菌抗体。
- 既往接种PPV23对多个血清型特异性OPA应答有负面影响,持续至少接种后1年。
研究设计与样本
- 本研究为原临床试验(NCT02370069)的随访分析,纳入57例既往接种PPV23的严重慢性肾脏病患者(组1)和72例未接种PPV23者(组2)。
- 于PCV13接种前及接种后第28天和第365天采集血清,测定针对13个疫苗血清型的调理吞噬活性(OPA)滴度。
主要发现
- 接种前,组1中3/13个血清型特异性抗体GMT显著高于组2。
- PCV13诱导两组GMT显著升高;接种后1年,组1中5/13个血清型GMT升高,组2中12/13个GMT升高。
- 第28天GMT增长倍数:组1为2.4(血清型1)至24.6(血清型6A),组2为4.3(血清型3)至67.0(血清型6A)。
- 组2第28天GMT增长倍数在血清型1、4、7F和18C显著大于组1。
- 原住民患者基线时血清型6B和23F的GMT显著高于非原住民;接种后第28天血清型5、6B、14、18C、19A、19F和23F的GMT显著高于非原住民。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Adults with chronic kidney disease (CKD) are at high risk of pneumococcal infections and recommended to receive pneumococcal immunization. Some studies suggest that previous immunization with 23-valent pneumococcal polysaccharide vaccine (PPV23) may decrease the immunogenicity of 13-valent pneumococcal conjugate vaccine (PCV13). Via quantitation of serum IgG, IgM, and IgA specific to 7 pneumococcal serotypes (3, 6B, 9V, 14, 19A, 19F, 23F), we recently found that the response to PCV13 in previously PPV23 immunized patients with severe CKD was inferior compared to PPV23 naïve patients. As a follow-up of the previous study, we assessed the titers of opsonizing antibodies specific to 13 vaccine serotypes in sera collected as per the original clinical trial protocol. Opsonophagocytic activity (OPA) titers were determined in 57 previously PPV23-immunized (Group 1) and 72 PPV23-naïve (Group 2) patients pre- and post-PCV13 immunization (days 28 and 365). Pre-immunization, the geometrical mean titers (GMT) for 3/13 serotype-specific antibodies were significantly higher in Group 1 than in Group 2. PCV13 induced a significant GMT rise in both groups; an increase in 5/13 serotype-specific GMTs in Group 1 and 12/13 GMTs in Group 2 was present at one year post-immunization. Fold increase in GMTs by day 28 ranged between 2.4 (serotype 1) and 24.6 (serotype 6A) in Group 1, and between 4.3 (serotype 3) and 67.0 (serotype 6A) in Group 2. The fold increase was significantly larger in Group 2 than in Group 1 for serotypes 1, 4, 7F, and 18C. Patients of Indigenous ethnic background had significantly higher GMT for serotypes 6B and 23F at baseline, and for serotypes 5, 6B, 14, 18C, 19A, 19F, and 23F at Day 28 post-immunization, compared to the non-Indigenous counterpart. Conclusions: Patients with severe CKD developed functionally active pneumococcal antibodies post-PCV13 immunization. Previously administered PPV23 had a negative impact on several serotype-specific OPA responses to PCV13 that lasted for at least one year post-immunization. ClinicalTrials.gov ID: NCT02370069.
引用
- Ulanova M, Huska B, Dubois S, et al. Opsonophagocytic activity against Streptococcus pneumoniae in Indigenous and non-Indigenous patients with severe chronic kidney disease immunized with 13-valent pneumococcal conjugate vaccine. Vaccine. 2022. PMID: 35738971. doi:10.1016/j.vaccine.2022.06.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。